Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and machine learning in oncology drug development, has achieved a key milestone in its global Phase 2 HARMONIC clinical trial. The company completed targeted patient enrollment in Japan for the trial evaluating LP-300, an investigational drug candidate for never-smoker non-small cell lung cancer (NSCLC). This achievement underscores the company's international expansion strategy and its focus on regions where never-smoker NSCLC has the highest prevalence.
CEO and President Panna Sharma stated, "Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence." He added that this milestone builds momentum as enrollment continues in Taiwan and the United States, bringing the company closer to generating clinical data that could establish LP-300 as a treatment option for this underserved patient population.
Lantern Pharma leverages its proprietary AI and machine learning platform, RADR, which utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms. This platform aims to accelerate drug development and reduce costs. On average, Lantern's newly developed drug programs have advanced from initial AI insights to first-in-human clinical trials in 2-3 years at approximately $2.5 million per program, significantly lower than industry averages.
The HARMONIC trial is designed to address the significant unmet medical need in never-smoker NSCLC patients, a population that often has distinct genetic profiles and limited treatment options. By focusing on Japan, where the prevalence of never-smoker lung cancer is notably high, Lantern Pharma aims to gather robust data that could support regulatory approvals and provide a new therapeutic option.
The company's pipeline spans multiple cancer indications, including solid tumors and blood cancers, with a growing portfolio of therapies developed through AI-driven insights. Lantern Pharma's approach is supported by world-class scientific advisors and collaborators, enhancing its ability to solve real-world problems in oncology drug development.
For more details, the full article is available at https://ibn.fm/eJM3g. Additional news and updates about Lantern Pharma can be found in the company's newsroom at https://ibn.fm/LTRN.
